Efficacy

Efficacy of Taltz (Ixekizumab) in Treating Psoriasis

Taltz (ixekizumab) is an immunosuppressant that is specifically designed to treat moderate to severe plaque psoriasis in adults who may benefit from systemic therapy or phototherapy. It is a biologic medication that works by targeting interleukin 17A (IL-17A), a protein that plays a significant role in the development of psoriatic plaques. Clinical trials have demonstrated that Taltz can lead to significant skin clearance. In these trials, many patients achieved a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) after just 12 weeks of treatment, and some even reached PASI 90 or PASI 100, indicating near-complete or complete clearance of skin lesions.

The efficacy of Taltz has been sustained in long-term studies, with a good proportion of patients maintaining significant skin clearance over a period of 60 weeks and beyond. The safety and efficacy of Taltz in the treatment of psoriatic arthritis have also been established, providing an additional benefit for psoriasis patients who may suffer from this related condition. However, it is important to note that individual responses to Taltz can vary, and some patients may experience a lesser degree of skin clearance.

Efficacy of Wezlana (Ustekinumab-auub) in Treating Psoriasis

Wezlana (ustekinumab-auub) is another biologic medication approved for the treatment of moderate to severe plaque psoriasis in adults. It is a biosimilar to the original ustekinumab, which means it is highly similar to an already FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety, purity, and potency. Ustekinumab targets interleukin 12 and interleukin 23, cytokines involved in inflammatory and immune responses, including the pathogenesis of psoriasis.

Clinical studies have shown that Wezlana is effective in achieving significant skin clearance in patients with plaque psoriasis. A majority of patients treated with ustekinumab can achieve PASI 75 within 12 weeks, and some patients may even attain PASI 90 or PASI 100, indicating an excellent response to treatment. The long-term efficacy of ustekinumab has been established, with many patients maintaining treatment response with continued therapy. As with other biologics, the response to Wezlana can vary among individuals.